How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials

Viviana Bazan, Francesca Toia, Antonio Galvano, Lorena Incorvaia, Giuseppe Badalamenti, Antonio Russo, Francesco Pantano, Bruno Vincenzi, Fiorella Guadagni, Giuseppe Tonini, Daniele Santini, Luisa Castellana

Risultato della ricerca: Articlepeer review

1 Citazioni (Scopus)

Abstract

Background: Zoledronic Acid is a bisphosphonate used in a 4-week schedule for the treatment of bone metastases. Some randomized trials supported its role also when administered every 12 weeks. Methods: we performed a systematic review and a meta-analysis in order to evaluate the two different schedules in terms of skeletal morbidity rate (SMR), skeletal related events (SRE) and adverse events (AEs). Results: our results showed a clinical difference favouring the 12-week schedule in terms of AEs (RR 1.17, 95% CI 1.06–1.29). No signifcant differences were found for SMR (RR 0.97, 95% CI 0.84–1.13) and SRE (RR 1.02, 95% CI 0.89–1.16). Conclusions: Our findings support in clinical practice the 12-week schedule an alternative to the standard 4-week schedule in advanced breast and prostate cancer, in particular when the clinical comorbidities of the patients suggest a higher risk of renal failure or hypocalcaemia.
Lingua originaleEnglish
pagine (da-a)68-75
Numero di pagine8
RivistaCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume142
Stato di pubblicazionePublished - 2019

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2720???
  • ???subjectarea.asjc.2700.2730???

Fingerprint

Entra nei temi di ricerca di 'How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials'. Insieme formano una fingerprint unica.

Cita questo